论文信息 - Fear of safety compromise with biosimilar anti-VEGF—perception or truth - 字舞流文

Fear of safety compromise with biosimilar anti-VEGF—perception or truth

B. Kuppermann | F. Bandello | Ashish Sharma | N. Parachuri | Nilesh Kumar

[1] N. Bressler,et al. Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes , 2021, British Journal of Ophthalmology.

[2] A. Loewenstein,et al. Biotherapeutics and immunogenicity: ophthalmic perspective , 2019, Eye.

[3] E. Keystone,et al. Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologists , 2015, Clinical Rheumatology.

[4] G. Fiorino,et al. Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization. , 2014, Journal of Crohn's & colitis.

[5] K. Eng,et al. Ranibizumab in neovascular age-related macular degeneration , 2006, Clinical interventions in aging.

[6] Susan Schneider,et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[7] V. Sharpe,et al. Competing interests , 2003, Nature Biotechnology.